Magnesium and ketamine have a common mechanism of action in the treatment of depression: an increase in GluN2B (NMDAR subunit) expression is related to the administration of both of the agents, as well as inhibition of phosphorylation of eEF2 (eukaryotic elongation factor 2) in cell culture and increase of the expression of BDNF in the hippocampus.
Magnesium And Ketamine In The Treatment Of Depression Read More »
Maurizio Fava, Marlene P. Freeman, Martina Flynn, Heidi Judge, Bettina B. Hoeppner, Cristina Cusin, Dawn F. Ionescu, Sanjay J. Mathew, Lee C. Chang, Dan V. Iosifescu, James Murrough, Charles Debattista, Alan F. Schatzberg, Madhukar H. Trivedi, Manish K Jha, Gerard Sanacora, Samuel T. Wilkinson, and George I. Papakostas Published 3 October 2018 | doi: 10.1038/s41380-018-0256-5
The concept of healthspan is relatively new in geroscience research, which seeks to understand the biological mechanisms of aging
How healthy is the healthspan concept? Read More »
Steven P. Cohen, MD; Anuj Bhatia, MBBS, MD; Asokumar Buvanendran, MD; Eric S. Schwenk, MD; Ajay D. Wasan, MD, MSc; Robert W. Hurley, MD, PhD; Eugene R. Viscusi, MD; Samer Narouze, MD, PhD; Fred N. Davis, MD; Elspeth C. Ritchie, MD, MPH; Timothy R. Lubenow, MD; and William M. Hooten, MD Published 1 July 2018
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain Read More »
Carola Rong, Caroline Park, Joshua D. Rosenblat, Mehala Subramaniapillai, Hannah Zuckerman, Dominika Fus, Yena L. Lee, Zihang Pan, Elisa Brietzke, Rodrigo B. Mansur, Danielle S. Cha, Leanna M. W. Lui and Roger S. McIntyre Published online: 17 April 2018 | https://doi.org/10.3390/ijerph15040771 Abstract Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive
Paul Glue, Shona M Neehoff, Natalie J Medlicott, Andrew Gray, Guy Kibby, Neil McNaughton First Published March 21, 2018 | https://doi.org/10.1177/0269881118762073 Abstract Objective: In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder
Ketamine is a potent N-methyl-d-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders. Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial
Ketamine for Social Anxiety Disorder Read More »
Samuel T. Wilkinson, M.D., Elizabeth D. Ballard, Ph.D., Michael H. Bloch, M.D., M.S., Sanjay J. Mathew, M.D., James W. Murrough, M.D., Ph.D., Adriana Feder, M.D., Peter Sos, M.D., Ph.D., Gang Wang, M.D., Carlos A. Zarate Jr., M.D., Gerard Sanacora, M.D., Ph.D. Published Online: 3 Oct 2017 | https://doi.org/10.1176/appi.ajp.2017.17040472 Abstract Objective Suicide is a public health
More recently it has been found that NAD+ is also required as a substrate by enzymes that regulate the expression of genes involved in cell viability and aging and in repair of damaged DNA.
How NAD+ Can Treat Degenerative Diseases Read More »
Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions. We present a series of patients with refractory migraine treated with intravenous ketamine in the hospital setting.
Ketamine for the Treatment of Chronic Migraines Read More »